Rubin Eyal — SEC Form 4 filings
SEC reporting owner CIK 1721411. 3 Form 4 filings on record with FilingPulse; latest filed 2026-09-21.
Transaction summary — filings shown
Covers all 3 filings on record, filed 2024-09-24 to 2026-09-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | Sr. VP and CFO | 2 | — | — | 2 |
| Nasus Pharma Ltd (NSRX) | Chief Financial Officer | 1 | — | — | — |
Form 4 filings — Rubin Eyal
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-21 | 4 | Nasus Pharma Ltd (NSRX) | Holdings only — no transactions reported | EDGAR |
| 2024-11-05 | 4/A | Protalix BioTherapeutics, Inc. (PLX) | Grant/award (A): 90,909 | EDGAR |
| 2024-09-24 | 4 | Protalix BioTherapeutics, Inc. (PLX) | Grant/award (A): 99,010 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-02 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1721411 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →